Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
01
12
2021
accepted:
09
09
2022
pubmed:
6
12
2022
medline:
3
1
2023
entrez:
5
12
2022
Statut:
ppublish
Résumé
The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41-49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71-0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66-1.04, P = 0.11). For patients with an LVEF of 41-49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57-0.88, P = 0.002) for the primary outcome (P
Identifiants
pubmed: 36471037
doi: 10.1038/s41591-022-02041-5
pii: 10.1038/s41591-022-02041-5
pmc: PMC9800272
doi:
Substances chimiques
Benzhydryl Compounds
0
empagliflozin
HDC1R2M35U
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2512-2520Informations de copyright
© 2022. The Author(s).
Références
Kelly, J. P. et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J. Am. Coll. Cardiol. 65, 1668–1682 (2015).
doi: 10.1016/j.jacc.2015.03.043
Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18, 891–975 (2016).
doi: 10.1002/ejhf.592
Bozkurt, B. et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J. Card. Fail. 27, 387–413 (2021).
doi: 10.1016/j.cardfail.2021.01.022
McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726 (2021).
doi: 10.1093/eurheartj/ehab368
Solomon, S. D. et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609–1620 (2019).
doi: 10.1056/NEJMoa1908655
Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383–1392 (2014).
doi: 10.1056/NEJMoa1313731
Yusuf, S. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777–781 (2003).
doi: 10.1016/S0140-6736(03)14285-7
Solomon, S. D. et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur. Heart J. 37, 455–462 (2016).
doi: 10.1093/eurheartj/ehv464
Lund, L. H. et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur. J. Heart Fail. 20, 1230–1239 (2018).
doi: 10.1002/ejhf.1149
Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
doi: 10.1056/NEJMoa2107038
Butler, J. et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 145, 184–193 (2022).
doi: 10.1161/CIRCULATIONAHA.121.057812
Solomon, S. D. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141, 352–361 (2020).
doi: 10.1161/CIRCULATIONAHA.119.044586
Packer, M., Zannad, F. & Anker, S. D. Heart failure and a preserved ejection fraction: a side-by-side examination of the PARAGON-HF and EMPEROR-Preserved trials. Circulation 144, 1193–1195 (2021).
doi: 10.1161/CIRCULATIONAHA.121.056657
Packer, M. et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation 144, 1284–1294 (2021).
doi: 10.1161/CIRCULATIONAHA.121.056824
Butler, J. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur. Heart J. 43, 416–426 (2022).
doi: 10.1093/eurheartj/ehab798
Bhatt, D. et al. Benefits of SGLT1/2 inhibition with sotagliflozin in heart failure with preserved ejection fraction. In The American College of Cardiology (ACC) 70th Annual Scientific Session & Expo Virtual Experience; May 15–17, 2021 https://www.acc.org/education-and-meetings/image-and-slide-gallery/~/media/B0EE906FD2D34B6AA29900BCE0681B8E.pdf (2021).
Nassif, M. E. et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat. Med. 27, 1954–1960 (2021).
doi: 10.1038/s41591-021-01536-x
Solomon, S. D. et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur. J. Heart Fail. 23, 1217–1225 (2021).
doi: 10.1002/ejhf.2249
Lam, C. S. & Solomon, S. D. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur. J. Heart Fail. 16, 1049–1055 (2014).
doi: 10.1002/ejhf.159
Butler, J., Anker, S. D. & Packer, M. Redefining heart failure with a reduced ejection fraction. JAMA 322, 1761–1762 (2019).
doi: 10.1001/jama.2019.15600
Anker, S. D. et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur. J. Heart Fail. 21, 1279–1287 (2019).
doi: 10.1002/ejhf.1596
Mishra, R. K. et al. Kansas City Cardiomyopathy Questionnaire score is associated with incident heart failure hospitalization in patients with chronic kidney disease without previously diagnosed heart failure: Chronic Renal Insufficiency Cohort Study. Circ. Heart Fail. 8, 702–708 (2015).
doi: 10.1161/CIRCHEARTFAILURE.115.002097
Savarese, G., Stolfo, D., Sinagra, G. & Lund, L. H. Heart failure with mid-range or mildly reduced ejection fraction. Nat. Rev. Cardiol. 19, 100–116 (2022).
doi: 10.1038/s41569-021-00605-5
Massie, B. M. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359, 2456–2467 (2008).
doi: 10.1056/NEJMoa0805450
Lin, D. Y., Wei, L. J., Yang, I. & Ying, Z. Semiparametric regression for the mean and rate functions of recurrent events. J. R. Stat. Soc. Ser. B Stat. Methodol. 62, 711–730 (2000).
doi: 10.1111/1467-9868.00259